API | simtuzumab

simtuzumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Simtuzumab is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
simtuzumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Lysyl oxidase homolog 2 (Homo sapiens) ^UniProt
- Lysyl oxidase homolog 2 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

ab0024 | ab-0024 | gs-6624 | simtuzumab

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Cholangitis (Phase 2)

Colorectal Neoplasms (Phase 2)

Hepatitis C (Phase 2)

HIV (Phase 2)

HIV Infections (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Liver Cirrhosis (Phase 2)

Neoplasms (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Pancreatic Neoplasms (Phase 2)

Primary Myelofibrosis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 13
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue